Skip to main content

Advertisement

Table 1 Characteristics of ART naive adults initiating ART in Uganda and Zimbabwe and surviving the first year of Therapy by main randomisation arm

From: Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART

  Baseline characteristics at
   randomisation and week 48
Randomisation in main DART trial LCM CDM
Total participants 1478 1482
Sex   
Female 970(66%) 952(64%)
WHO stage   
2 331(22%) 291(20%)
3 827(56%) 844(57%)
4 320(22%) 345(23%)
BMI   
<20 489(33%) 515(35%)
20-27 846(58%) 831(56%)
>27 130(9%) 127(9%)
CD4 cells/ μL   
Median (IQR) 84(33-138) 86(31-140)
Age(years) at ART initiation   
Median (IQR) 37(32-42) 36(32-42)
18-35 589(40%) 593(40%)
35-50 792(54%) 796(54%)
>50 97(6%) 93(6%)
Initial ART regimen   
Tenofovir (TDF) 1075(73%) 1087(73%)
Nevirapine (NVP) 260(18%) 251(17%)
Abacavir (ABC) 143(10%) 142(10%)
Follow up at 48 weeks   
STI/CT randomisation   
Not randomised 1061(72%) 1082(73%)
Randomised to STI 209(14%) 203(14%)
Randomised to CT 208(14%) 197(13%)
CD4 cells/ μL at week 48   
Median (IQR) 201(139-283) 200(141-280)
Weight at week 48   
Median(IQR) 63(57-71) 63(56-71)